Sources: TNFA Website.
-----
As mentioned above, (Nasdaq: TNFA) has several potential catalysts to consider starting right now. Take a look:
No. 1 TNFA Potential Catalyst - Could A Really Low Float Create A Volatile Environment?
According to info from the Yahoo Finance website, TNFA has a low float.
The website reports this profile to have roughly 2.39Mn shares in its float.
Why is that important? It's important on one crucial level. Volatility potential.
Could positive company news early in 2025 provide a breakout spark?
-----
No. 2 TNFA Potential Catalyst - Positive Clinical Data Milestone Supports Expanding Studies (Successfully Completed An FDA-Recommended Study).
TNF Pharmaceuticals Announces Positive Clinical Data Supporting Clinical Trial Expansion
Set to begin larger Phase 2b study in sarcopenia and new trial in GLP-1-induced sarcopenia and frailty
Transformative potential for novel TNF-alpha inhibitor drug:Estimated $4Bn TNF inhibitor market and $50Bn GLP-1 agonist market
BALTIMORE, January 15, 2025--(BUSINESS WIRE)--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) ("TNFA" or the "Company"), a clinical stage biopharmaceutical company committed to developing novel oral therapies for autoimmune and inflammatory conditions, today announced that it has achieved a key safety data milestone supporting expanded and longer-term clinical studies of its novel TNF-alpha (TNF-α) inhibitor drug, isomyosamine, in multiple indications.
The Company successfully completed an FDA-recommended study of isomyosamine that demonstrated clinical safety throughout 13 weeks of treatment at all dose levels evaluated.
"Positive data from this milestone study confirms isomyosamine's historically strong safety profile and enables us to extend the duration of future clinical trials," said Mitchell Glass, M.D., President and Chief Medical Officer of TNFA. "We believe we are fully equipped to advance our comprehensive isomyosamine platform in a longer-term clinical trial in sarcopenia and future studies in multiple conditions associated with immunometabolic dysregulation."
...
Read the full article here.
-----
No. 3 TNFA Potential Catalyst - Key Study Series Launched (The Ball Starts Rolling).
TNF Pharmaceuticals Launches Study Series Aimed at Preserving Lean Muscle Mass During GLP-1 Wei-ght Lo-ss Treatment
- Series of studies to observe signals of inflammation and TNF-alpha levels in patients taking GLP-1s including We-govy® or O-zempic®
- Lean body mass accounts for up to 40% of weight loss from GLP-1 treatments
- Potential entry into high growth GLP-1 market of nearly $50Bn in 2024, projected value of $100Bn by 2029
BALTIMORE, January 29, 2025--(BUSINESS WIRE)--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) ("TNF" or the "Company"), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, today announced that it has initiated the first in a series of studies to evaluate the impact of its novel oral TNF-alpha (TNF-α) inhibitor drug, isomyosamine, in preserving lean muscle mass during and after GLP-1 treatment for wei-ght lo-ss and chronic weight management.
"The body of evidence for the GLP-1 drug class shows that up to 40% of total wei-ght lo-ss in GLP-1 patients is lean body mass including skeletal muscle mass,1" said Mitchell Glass, M.D., President and Chief Medical Officer of TNF. "The purpose of our clinical study series is to assess isomyosamine's potential to preserve lean muscle mass during and following GLP-1 wei-ght loss in chronic overweight and obese patients of all age groups."
...
Read the full article here.
-----
No. 4 TNFA Potential Catalyst - Oversold Leaning Technicals Suggest Healthy Reversal/Bounce Potential Could Be Significant!
At 4:00PM EST Friday, Barchart was reporting multiple oversold leaning technical indicators for TNFA.
These technicals could be signaling a healthy reversal is approaching in the near term.
Here's the definition of a "reversal" from Investopedia:
"A reversal is a change in the price direction of an asset. A reversal can occur to the upside or downside. Following an uptrend, a reversal would be to the downside. Following a downtrend, a reversal would be to the upside. Reversals are based on overall price direction and are not typically based on one or two periods/bars on a chart."
Here's the technicals to pay close attention to (as of 4:00PM EST Friday):
- 9-Day Relative Strength Index: 27.69%
- 14-Day Relative Strength Index: 31.46%
When these numbers drop down to the 30% range and lower, they can be viewed as being in oversold territory. While in this territory, they can paint the picture of a profile that is undervalued.
- 14-Day Raw Stochastic: 8.12%
- 14-Day Williams %R: 91.88%
As the Raw Stochastic nears the 10% range and lower and the Williams %R nears the 90% range or higher, these technical indicators may also be viewed as oversold and undervalued.
Keep an eye on these technicals closely.
-----
No. 5 TNFA Potential Catalyst - A Recent In-vest-ment Screams Confidence In TNFA's MYMD-1 Potential.
TNF Pharmaceuticals Announces Strategic Equity In-vest-ment Priced at a Premium to Market
- Prevail Partners, LLC in-vest-ment priced at more than a 40% premium to market
- Prevail InfoWorks, Inc. to act as Clinical Research Organization partner; global full service CRO with hundreds of clinical trials over a decade
- TNF Pharmaceuticals fully funded for clinical trials for next two years
BALTIMORE, October 02, 2024--(BUSINESS WIRE)--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) ("TNFA" or the "Company"), a clinical stage biopharmaceutical company committed to developing novel oral therapies for autoimmune and inflammatory conditions, today announced that it has secured a strategic equity in-vest-ment, priced at a 20% premium to a 30-trading days volume weighted average price (VWAP), from Prevail Partners, LLC, a U.S. in-vest-ment fund focused on life sciences companies. The Company has engaged global full-service Clinical Research Organization (CRO) Prevail InfoWorks, Inc., an affiliate of Prevail Partners, to provide clinical services for the next Phase 2 clinical study using our proprietary drug in sarcopenia/frailty.
"Prevail Partners, a corporate strategic evergreen fund, selects life sciences companies developing novel and breakthrough therapeutics. The fund's in-vest-ment in TNFA points to their confidence in our potent oral synthetic TNF-alpha (TNFα-inhibitor) MYMD-1's potential to transform how TNFα-based diseases are treated," said Mitchell Glass, M.D., President and Chief Medical Officer of the Company. "Prevail InfoWorks recently received industry recognition as the most advanced tech-enabled CRO, and our study will benefit from their unique experience and expertise. We are excited about our new partners and our close alignment of interests in executing our upcoming clinical studies efficiently and effectively."
...
Read the full article here.
-----
(Nasdaq: TNFA) Recap - 5 Potential Catalysts That Could Generate Buzz
No. 1 - Could A Really Low Float Create A Volatile Environment?
No. 2 - Positive Clinical Data Milestone Supports Expanding Studies (Successfully Completed An FDA-Recommended Study).
No. 3 - Key Study Series Launched (The Ball Starts Rolling).
No. 4 - Oversold Leaning Technicals Suggest Healthy Reversal/Bounce Potential Could Be Significant!
No. 5 - A Recent In-vest-ment Screams Confidence In TNFA's MYMD-1 Potential.
-----
Coverage is officially initiated on TNF Pharmaceuticals, Inc. (Nasdaq: TNFA).
If updates pop up, I'll get them out quickly. Talk soon.
Sincerely,
Kai Parker
StockWireNews
(Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)
